Emcure Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, Emcure Pharmaceuticals (EMCURE) reported revenue ₹2,484 Cr and net profit ₹244 Cr — revenue +17.1% YoY. For annual financials, live price and key ratios, visit Emcure Pharmaceuticals share price today.
EMCURE Quarterly Results — Revenue, Profit & EPS Highlights
Emcure Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Browse EMCURE income statement for revenue, profit, balance sheet and cash flow data.
- Revenue of ₹2,484 Cr in Mar 2026 (-3.8% vs Jun 2026, +17.1% vs Mar 2025)
- Net Profit of ₹244 Cr in Mar 2026 (-16.7% vs Jun 2026, +23.9% vs Mar 2025)
- EBITDA of ₹494 Cr in Mar 2026 (-7.7% vs Jun 2026)
- Operating Margin of 19.0% in Mar 2026 (-2.0pp vs Jun 2026)
- Earnings Per Share of ₹12.84 in Mar 2026 (-17.2% vs Jun 2026)
Emcure Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
EMCURE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 2,484 | 2,583 | 2,273 | 2,121 | 2,104 | -3.8% | 17.1% |
| Net Profit (₹ Cr) | 244 | 293 | 251 | 197 | 215 | - | - |
| EBITDA (₹ Cr) | 494 | 535 | 479 | 397 | 417 | - | - |
| EPS (₹) | 12.84 | 15.50 | 12.85 | 9.97 | 10.92 | - | - |
| Operating Margin (%) | 19.0% | 21.0% | 21.0% | 19.0% | 20.0% | - | - |
EMCURE Share Price Trend — 1-Year Movement Across Quarterly Results
Emcure Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore EMCURE price trends to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
EMCURE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Emcure Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1900.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 168.1 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8560.0 | 2,986 | 751 | -5.0% | - | 25.2% | 302.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 5013.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 435.5 |
|
Cipla
Mar 2026 |
₹114,875.60 Cr | 1422.0 | 6,612 | 543 | -9.3% | - | 8.2% | 207.0 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1104.5 | 7,569 | 1,341 | -4.3% | - | 17.7% | 87.3 |
All amounts in ₹ Crores